Table 1. Main clinical characteristics of the cohort. Differences between individuals with plasma zinc at admission <50mcg/dl and *≥50mcg/dl.*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|   | *Overall* | *<50* µg/*/dl* |  | *≥50* µg/*/dl* | *p-value* |
| **Cohort Characteristics** | n=249 |   | n=58 |   | n=191 |   |
| Median age, years (IQR) | 65 | (54-75) \* | 65 | (59-75) |   | 64 | (53-74) | 0.363 |   |
| Male sex (%) | 127 | (51%) | 30 | (51%) |   | 97 | (51%) | 0.929 |   |
| Barthel index at admission, median (IQR) | 100 | (100-100) | 100 | (100-100) |   | 100 | (100-100) | 0.448 |   |
| Homelessness (%) | 2 | (0.89%) | 0 | (0%) |   | 2 | (1.53%) | 0.231 |   |
| **Comorbidities** |   |   |   |   |   |   |   |   |   |
| Current smoker (%) | 23 | (9.3%) | 4 | (7%) |   | 19 | (10%) | 0.482 |   |
| Hypertension (%) | 141 | (56%) | 33 | (57%) |   | 108 | (57%) | 0.962 |   |
| Diabetes Mellitus (%) | 53 | (21%) | 17 | (29%) |   | 36 | (19%) | 0.088 |   |
| Chronic lung disease (%) | 22 | (9%) | 9 | (16%) |   | 13 | (7%) | 0.041 |   |
| Chronic heart disease (%) | 37 | (14%) | 11 | (19%) |   | 26 | (14%) | 0.315 |   |
| Chronic renal disease (%) | 70 | (12%) | 22 | (38%) |   | 48 | (25%) | 0.058 |   |
| Chronic liver disease (%) | 18 | (7%) | 1 | (2%) |   | 17 | (9%) | 0.065 |   |
| Dementia (%) | 8 | (3%) | 2 | (3%) |   | 6 | (3%) | 0.908 |   |
| HIV-infection (%) | 5 | (2%) | 1 | (2%) |   | 4 | (2%) | 0.865 |   |
| Active cancer (%) | 7 | (3%) | 3 | (5%) |   | 4 | (2%) | 0.214 |   |
| ACE inhibitors (%) | 61 | (24%) | 12 | (21%) |   | 49 | (26%) | 0.441 |   |
| Charlson Comorbidy Index, median (IQR) | 1 | (0-3) | 1 | (0-3) |   | 1 | (0-2) | 0.247 |   |
| **Symptoms at onset** |   |   |   |   |   |   |   |   |   |
| Dyspnoea (%) | 151 | (60%) | 42 | (72%) |   | 109 | (57%) | 0.036 |   |
| Fever (%) | 203 | (81%) | 45 | (77%) |   | 158 | (82%) | 0.377 |   |
| Cough (%) | 198 | (79%) | 43 | (74%) |   | 155 | (81%) | 0.246 |   |
| Diarrhea (%) | 68 | (27%) | 12 | (21%) |   | 56 | (29%) | 0.196 |   |
| Headache (%) | 43 | (17%) | 8 | (14%) |   | 35 | (18%) | 0.424 |   |
| Anosmia (%) | 35 | (14%) | 7 | (12%) |   | 28 | (15%) | 0.619 |   |
| **Clinical markers at onset** |   |   |   |   |   |   |   |   |   |
| Median C-Reactive Protein mg/dl (IQR) | 7.5 | (3.5-15.2) | 14.6 | (5-24) |   | 7 | (3-13) | 0.037 |   |
| Median lymphocyte count /ml (IQRS) | 1.02 | (0.71-1.4) | 0.82 | (0.57-1.18) |   | 1.1 | (0.78-1.48) | 0.598 |   |
| Median IL-6 pg/ml (IQR) | 42 | (15-89) | 77 | (39-145) |   | 32 | (11-71) | <0.001 |   |
| Median Lactate Dehydrogenase UI/l (IQR) | 288 | (241-345) | 356 | (275-483) |   | 274 | (231-362) | 0.001 |   |
| Median D-Dimer UI/l (IQR) | 800 | (470-1450) | 935 | (540-1700) |   | 800 | (460-1215) | 0.048 |   |
| Median PaFi (IQR) | 177 | (100-299) | 124 | (91-181) |   | 219 | (106-314) | <0.001 |   |
| Median MEWS (IQR) | 2 | (1-3) | 2 | (2-3) |   | 2 | (1-3) | 0.005 |   |
| Median serum Zinc, mcg/ml (IQR) | 61 | (50-71) | 43 | (39-48) |   | 66 | (58-74) | <0.001 |   |
| **Treatment** |   |   |   |   |   |   |   |   |   |
| Hydroxycholoroquine (%) | 248 | (99.5%) | 58 | (100%) |   | 190 | (99%) | 0.372 |   |
| Azythromicin (%) | 231 | (95%) | 57 | (95%) |   | 174 | (95%) | 0.766 |   |
| Tocilizumab (%) | 55 | (23%) | 23 | (40%) |   | 32 | (17%) | <0.001 |   |
| Dexamethasone (%) | 64 | (26%) | 24 | (41%) |   | 40 | (21%) | <0.001 |   |
| Methylprednisolone (%) | 59 | (24%) | 26 | (45%) |   | 33 | (17%) | <0.001 |   |
| **Clinical Outcomes** |   |   |   |   |   |   |   |   |   |
| Median Time to clinical stability days (IQR) | 10 | (6-18) | 25 | (14-36) |   | 8 | (5-14) | <0.001 |   |
| ICU admission (%) | 70 | (28%) | 36 | (62%) |   | 34 | (18%) | <0.001 |   |
| Death (%) | 21 | (9%) | 12 | (21%) |   | 9 | (5%) | <0.001 |   |
|   |
|   |
|   |